GlycoFlux™ Human ALG3 Overexpression Glycoengineered Cell (CAT#: GLJF-0925-JF131)

Description	GlycoFlux™ human ALG3 overexpression glycoengineered cell is a stable cell line engineered to increase ALG3 expression, a key enzyme in N-glycosylation that adds alpha-1,3 mannose during glycan precursor assembly. As a glycoengineered model, it supports studies of congenital disorders of glycosylation (CDG-Id), abnormal protein glycosylation, and neurological disease mechanisms.
Product Type	Overexpression Cell Lines
Cell Line	As requested by the client.

Cell Viability	>90%
Sterility Test	The sterility test indicated an absence of microbial growth.
Identity Test	STR identification
Mycoplasma Test	Negative
Virus Test	Negative for HIV, HBV and HCV.
Genetic Stability Testing	We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.
Validation	qPCR, Sanger Sequencing
Application	Mechanistic studies; Exploration of glycosylation and signaling pathways in cancer, metabolic, and immune-related diseases; Drug target validation and other functional assays.
Size	1 M cells/vial*2
Product Format	Frozen
Shipping	Dry ice
Availability Status	Made to order
Handling Notes	Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.
Product Disclaimer	This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.

Target	ALG3
Full Name	Alg3 Alpha-1,3- Mannosyltransferase
Alternative Name	NOT56L; D16Ertd36e; CDGS4; Not56
Location	3q27.1
Gene ID	10195
Summary	Key player in N-glycosylation, adding alpha 1,3 mannose (dol-P-Man to Man5GlcNAc2-PP-Dol); disruptions linked to CDG-Id (congenital disorder of glycosylation type Id), causing abnormal N-glycosylation and potential neurological issues.